Assessing Drug Administration Techniques in Zebrafish Models of Neurological Disease
Abstract
:1. Introduction
2. Challenges in Zebrafish Neurological Disease Research
3. Insights into Drug Administration in Zebrafish Model
3.1. Direct Administration Techniques
3.1.1. Bath Immersion
3.1.2. Zebrafish Embryonic Microinjection
3.1.3. Oral Administration
3.2. Targeted Drug Delivery Systems
3.2.1. Genetic Manipulation Techniques
3.2.2. Nanoparticles
3.2.3. Hydrogels
4. Drug Delivery Techniques Used in Zebrafish Neurological Disease Models
4.1. Alzheimer’s Disease
4.2. Parkinson’s Disease
4.3. Traumatic Brain Injury (TBI) and Stroke
4.4. Autism Spectrum Disorders
4.5. Amyotrophic Lateral Sclerosis
5. Concluding Remarks and Perspectives
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Kari, G.; Rodeck, U.; Dicker, A.P. Zebrafish: An emerging model system for human disease and drug discovery. Clin. Pharmacol. Ther. 2007, 82, 70–80. [Google Scholar] [CrossRef] [PubMed]
- Spence, R.; Gerlach, G.; Lawrence, C.; Smith, C. The behaviour and ecology of the zebrafish, Danio Rerio. Biol. Rev. Camb. Philos. Soc. 2008, 83, 13–34. [Google Scholar] [CrossRef]
- Nasiadka, A.; Clark, M.D. Zebrafish breeding in the laboratory environment. ILAR J. 2012, 53, 161–168. [Google Scholar] [CrossRef]
- Parng, C.; Seng, W.L.; Semino, C.; McGrath, P. Zebrafish: A preclinical model for drug screening. Assay Drug Dev. Technol. 2002, 1 Pt 1, 41–48. [Google Scholar] [CrossRef] [PubMed]
- Crilly, S.; Parry-Jones, A.; Wang, X.; Selley, J.N.; Cook, J.; Tapia, V.S.; Anderson, C.S.; Allan, S.M.; Kasher, P.R. Zebrafish drug screening identifies candidate therapies for neuroprotection after spontaneous intracerebral haemorrhage. Dis. Models Mech. 2022, 15, dmm049227. [Google Scholar] [CrossRef]
- McGown, A.; Shaw, D.P.; Ramesh, T. ZNStress: A high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis. Mol. Neurodegener. 2016, 11, 56. [Google Scholar] [CrossRef]
- Lawrence, C.; Adatto, I.; Best, J.; James, A.; Maloney, K. Generation time of zebrafish (Danio rerio) and medakas (Oryzias latipes) housed in the same aquaculture facility. Lab. Anim. 2012, 41, 158–165. [Google Scholar] [CrossRef] [PubMed]
- Blader, P.; Strahle, U. Zebrafish developmental genetics and central nervous system development. Hum. Mol. Genet. 2000, 9, 945–951. [Google Scholar] [CrossRef]
- Fulwiler, C.; Gilbert, W. Zebrafish embryology and neural development. Curr. Opin. Cell Biol. 1991, 3, 988–991. [Google Scholar] [CrossRef] [PubMed]
- Kimmel, C.B.; Ballard, W.W.; Kimmel, S.R.; Ullmann, B.; Schilling, T.F. Stages of embryonic development of the zebrafish. Dev. Dyn. 1995, 203, 253–310. [Google Scholar] [CrossRef] [PubMed]
- Basnet, R.M.; Zizioli, D.; Taweedet, S.; Finazzi, D.; Memo, M. Zebrafish Larvae as a Behavioral Model in Neuropharmacology. Biomedicines 2019, 7, 23. [Google Scholar] [CrossRef]
- Ellis, L.D.; Soanes, K.H. A larval zebrafish model of bipolar disorder as a screening platform for neuro-therapeutics. Behav. Brain Res. 2012, 233, 450–457. [Google Scholar] [CrossRef]
- Holtze, S.; Gorshkova, E.; Braude, S.; Cellerino, A.; Dammann, P.; Hildebrandt, T.B.; Hoeflich, A.; Hoffmann, S.; Koch, P.; Terzibasi Tozzini, E.; et al. Alternative Animal Models of Aging Research. Front. Mol. Biosci. 2021, 8, 660959. [Google Scholar] [CrossRef]
- Zhdanova, I.V.; Yu, L.; Lopez-Patino, M.; Shang, E.; Kishi, S.; Guelin, E. Aging of the circadian system in zebrafish and the effects of melatonin on sleep and cognitive performance. Brain Res. Bull. 2008, 75, 433–441. [Google Scholar] [CrossRef]
- Yu, L.; Tucci, V.; Kishi, S.; Zhdanova, I.V. Cognitive aging in zebrafish. PLoS ONE 2006, 1, e14. [Google Scholar] [CrossRef]
- Volkov, M.; Machikhin, A.; Bukova, V.; Khokhlov, D.; Burlakov, A.; Krylov, V. Optical transparency and label-free vessel imaging of zebrafish larvae in shortwave infrared range as a tool for prolonged studying of cardiovascular system development. Sci. Rep. 2022, 12, 20884. [Google Scholar] [CrossRef]
- Cooper, M.S.; D’Amico, L.A.; Henry, C.A. Analyzing morphogenetic cell behaviors in vitally stained zebrafish embryos. Methods Mol. Biol. 1999, 122, 185–204. [Google Scholar]
- Ahrens, M.B.; Orger, M.B.; Robson, D.N.; Li, J.M.; Keller, P.J. Whole-brain functional imaging at cellular resolution using light-sheet microscopy. Nat. Methods 2013, 10, 413–420. [Google Scholar] [CrossRef]
- Panier, T.; Romano, S.A.; Olive, R.; Pietri, T.; Sumbre, G.; Candelier, R.; Debregeas, G. Fast functional imaging of multiple brain regions in intact zebrafish larvae using selective plane illumination microscopy. Front. Neural Circuits 2013, 7, 65. [Google Scholar] [CrossRef]
- Godinho, L. Live imaging of zebrafish development. Cold Spring Harb. Protoc. 2011, 2011, 770–777. [Google Scholar] [PubMed]
- Cong, L.; Wang, Z.; Chai, Y.; Hang, W.; Shang, C.; Yang, W.; Bai, L.; Du, J.; Wang, K.; Wen, Q. Rapid whole brain imaging of neural activity in freely behaving larval zebrafish (Danio rerio). Elife 2017, 6, e28158. [Google Scholar] [CrossRef]
- Higashijima, S.; Hotta, Y.; Okamoto, H. Visualization of cranial motor neurons in live transgenic zebrafish expressing green fluorescent protein under the control of the islet-1 promoter/enhancer. J. Neurosci. 2000, 20, 206–218. [Google Scholar] [CrossRef]
- Randlett, O.; Wee, C.L.; Naumann, E.A.; Nnaemeka, O.; Schoppik, D.; Fitzgerald, J.E.; Portugues, R.; Lacoste, A.M.; Riegler, C.; Engert, F.; et al. Whole-brain activity mapping onto a zebrafish brain atlas. Nat. Methods 2015, 12, 1039–1046. [Google Scholar] [CrossRef]
- Wullimann, M.F.; Rupp, B.; Reichert, H. Neuroanatomy of the Zebrafish Brain; Birkhäuser: Basel, Switzerland, 1996; 144p. [Google Scholar]
- Panula, P.; Sallinen, V.; Sundvik, M.; Kolehmainen, J.; Torkko, V.; Tiittula, A.; Moshnyakov, M.; Podlasz, P. Modulatory neurotransmitter systems and behavior: Towards zebrafish models of neurodegenerative diseases. Zebrafish 2006, 3, 235–247. [Google Scholar] [CrossRef]
- Haug, M.F.; Gesemann, M.; Mueller, T.; Neuhauss, S.C. Phylogeny and expression divergence of metabotropic glutamate receptor genes in the brain of zebrafish (Danio rerio). J. Comp. Neurol. 2013, 521, 1533–1560. [Google Scholar] [CrossRef]
- Delgado, L.; Schmachtenberg, O. Immunohistochemical localization of GABA, GAD65, and the receptor subunits GABAAalpha1 and GABAB1 in the zebrafish cerebellum. Cerebellum 2008, 7, 444–450. [Google Scholar] [CrossRef]
- Lillesaar, C. The serotonergic system in fish. J. Chem. Neuroanat. 2011, 41, 294–308. [Google Scholar] [CrossRef]
- Mueller, T.; Vernier, P.; Wullimann, M.F. The adult central nervous cholinergic system of a neurogenetic model animal, the zebrafish Danio rerio. Brain Res. 2004, 1011, 156–169. [Google Scholar] [CrossRef]
- Mueller, T.; Wullimann, M.F. An evolutionary interpretation of teleostean forebrain anatomy. Brain Behav. Evol. 2009, 74, 30–42. [Google Scholar] [CrossRef]
- Rink, E.; Wullimann, M.F. Connections of the ventral telencephalon (subpallium) in the zebrafish (Danio rerio). Brain Res. 2004, 1011, 206–220. [Google Scholar] [CrossRef]
- Boehmler, W.; Obrecht-Pflumio, S.; Canfield, V.; Thisse, C.; Thisse, B.; Levenson, R. Evolution and expression of D2 and D3 dopamine receptor genes in zebrafish. Dev. Dyn. 2004, 230, 481–493. [Google Scholar] [CrossRef]
- Howe, K.; Clark, M.D.; Torroja, C.F.; Torrance, J.; Berthelot, C.; Muffato, M.; Collins, J.E.; Humphray, S.; McLaren, K.; Matthews, L.; et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature 2013, 496, 498–503. [Google Scholar] [CrossRef] [PubMed]
- Postlethwait, J.H.; Woods, I.G.; Ngo-Hazelett, P.; Yan, Y.L.; Kelly, P.D.; Chu, F.; Huang, H.; Hill-Force, A.; Talbot, W.S. Zebrafish comparative genomics and the origins of vertebrate chromosomes. Genome Res. 2000, 10, 1890–1902. [Google Scholar] [CrossRef] [PubMed]
- Newman, M.; Verdile, G.; Martins, R.N.; Lardelli, M. Zebrafish as a tool in Alzheimer’s disease research. Biochim. Biophys Acta 2011, 1812, 346–352. [Google Scholar] [CrossRef] [PubMed]
- Barnhill, L.M.; Murata, H.; Bronstein, J.M. Studying the Pathophysiology of Parkinson’s Disease Using Zebrafish. Biomedicines 2020, 8, 197. [Google Scholar] [CrossRef]
- Karlovich, C.A.; John, R.M.; Ramirez, L.; Stainier, D.Y.; Myers, R.M. Characterization of the Huntington’s disease (HD) gene homologue in the zebrafish Danio rerio. Gene 1998, 217, 117–125. [Google Scholar] [CrossRef] [PubMed]
- Da Costa, M.M.; Allen, C.E.; Higginbottom, A.; Ramesh, T.; Shaw, P.J.; McDermott, C.J. A new zebrafish model produced by TILLING of SOD1-related amyotrophic lateral sclerosis replicates key features of the disease and represents a tool for in vivo therapeutic screening. Dis. Model Mech. 2014, 7, 73–81. [Google Scholar] [CrossRef]
- Iyer, S.; Subramanian, V.; Acharya, K.R. C9orf72, a protein associated with amyotrophic lateral sclerosis (ALS) is a guanine nucleotide exchange factor. PeerJ 2018, 6, e5815. [Google Scholar] [CrossRef]
- Nusslein-Volhard, C. The zebrafish issue of Development. Development 2012, 139, 4099–4103. [Google Scholar] [CrossRef]
- Foley, J.E.; Yeh, J.R.; Maeder, M.L.; Reyon, D.; Sander, J.D.; Peterson, R.T.; Joung, J.K. Rapid mutation of endogenous zebrafish genes using zinc finger nucleases made by Oligomerized Pool ENgineering (OPEN). PLoS ONE 2009, 4, e4348. [Google Scholar] [CrossRef]
- Meng, X.; Noyes, M.B.; Zhu, L.J.; Lawson, N.D.; Wolfe, S.A. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nat. Biotechnol. 2008, 26, 695–701. [Google Scholar] [CrossRef]
- Sander, J.D.; Cade, L.; Khayter, C.; Reyon, D.; Peterson, R.T.; Joung, J.K.; Yeh, J.R. Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nat. Biotechnol. 2011, 29, 697–698. [Google Scholar] [CrossRef] [PubMed]
- Dahlem, T.J.; Hoshijima, K.; Jurynec, M.J.; Gunther, D.; Starker, C.G.; Locke, A.S.; Weis, A.M.; Voytas, D.F.; Grunwald, D.J. Simple methods for generating and detecting locus-specific mutations induced with TALENs in the zebrafish genome. PLoS Genet. 2012, 8, e1002861. [Google Scholar] [CrossRef]
- Hwang, W.Y.; Fu, Y.; Reyon, D.; Maeder, M.L.; Tsai, S.Q.; Sander, J.D.; Peterson, R.T.; Yeh, J.R.; Joung, J.K. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 2013, 31, 227–229. [Google Scholar] [CrossRef] [PubMed]
- Haffter, P.; Granato, M.; Brand, M.; Mullins, M.C.; Hammerschmidt, M.; Kane, D.A.; Odenthal, J.; van Eeden, F.J.; Jiang, Y.J.; Heisenberg, C.P.; et al. The identification of genes with unique and essential functions in the development of the zebrafish, Danio rerio. Development 1996, 123, 1–36. [Google Scholar] [CrossRef] [PubMed]
- Talbot, W.S.; Hopkins, N. Zebrafish mutations and functional analysis of the vertebrate genome. Genes Dev. 2000, 14, 755–762. [Google Scholar] [CrossRef]
- Phillips, J.B.; Westerfield, M. Zebrafish models in translational research: Tipping the scales toward advancements in human health. Dis. Model Mech. 2014, 7, 739–743. [Google Scholar] [CrossRef] [PubMed]
- Bradford, Y.M.; Toro, S.; Ramachandran, S.; Ruzicka, L.; Howe, D.G.; Eagle, A.; Kalita, P.; Martin, R.; Taylor Moxon, S.A.; Schaper, K.; et al. Zebrafish Models of Human Disease: Gaining Insight into Human Disease at ZFIN. ILAR J. 2017, 58, 4–16. [Google Scholar] [CrossRef]
- Marcon, M.; Herrmann, A.P.; Mocelin, R.; Rambo, C.L.; Koakoski, G.; Abreu, M.S.; Conterato, G.M.; Kist, L.W.; Bogo, M.R.; Zanatta, L.; et al. Prevention of unpredictable chronic stress-related phenomena in zebrafish exposed to bromazepam, fluoxetine and nortriptyline. Psychopharmacology 2016, 233, 3815–3824. [Google Scholar] [CrossRef]
- Lundegaard, P.R.; Anastasaki, C.; Grant, N.J.; Sillito, R.R.; Zich, J.; Zeng, Z.; Paranthaman, K.; Larsen, A.P.; Armstrong, J.D.; Porteous, D.J.; et al. MEK Inhibitors Reverse cAMP-Mediated Anxiety in Zebrafish. Chem. Biol. 2015, 22, 1335–1346. [Google Scholar] [CrossRef]
- Maria Virginia, C.; Manila, C. Zebrafish as screening model for detecting toxicity and drugs efficacy. Zebrafish Screen. Model Detect. Toxic. Drugs Effic. 2018, 3, 4. [Google Scholar]
- Egan, R.J.; Bergner, C.L.; Hart, P.C.; Cachat, J.M.; Canavello, P.R.; Elegante, M.F.; Elkhayat, S.I.; Bartels, B.K.; Tien, A.K.; Tien, D.H.; et al. Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish. Behav. Brain Res. 2009, 205, 38–44. [Google Scholar] [CrossRef] [PubMed]
- Tan, J.K.; Nazar, F.H.; Makpol, S.; Teoh, S.L. Zebrafish: A Pharmacological Model for Learning and Memory Research. Molecules 2022, 27, 7374. [Google Scholar] [CrossRef]
- Blaser, R.E.; Vira, D.G. Experiments on learning in zebrafish (Danio rerio): A promising model of neurocognitive function. Neurosci. Biobehav. Rev. 2014, 42, 224–231. [Google Scholar] [CrossRef] [PubMed]
- Gould, G.G. Modified Associative Learning T-Maze Test for Zebrafish (Danio rerio) and Other Small Teleost Fish. In Zebrafish Neurobehavioral Protocols; Kalueff, A.V., Cachat, J.M., Eds.; Humana Press: Totowa, NJ, USA, 2011; pp. 61–73. [Google Scholar]
- Bault, Z.A.; Peterson, S.M.; Freeman, J.L. Directional and color preference in adult zebrafish: Implications in behavioral and learning assays in neurotoxicology studies. J. Appl. Toxicol. 2015, 35, 1502–1510. [Google Scholar] [CrossRef] [PubMed]
- Haghani, S.; Karia, M.; Cheng, R.K.; Mathuru, A.S. An Automated Assay System to Study Novel Tank Induced Anxiety. Front. Behav. Neurosci. 2019, 13, 180. [Google Scholar] [CrossRef] [PubMed]
- Song, P.; Pimplikar, S.W. Knockdown of amyloid precursor protein in zebrafish causes defects in motor axon outgrowth. PLoS ONE 2012, 7, e34209. [Google Scholar] [CrossRef]
- Bhattarai, P.; Turgutalp, B.; Kizil, C. Zebrafish as an Experimental and Preclinical Model for Alzheimer’s Disease. ACS Chem. Neurosci. 2022, 13, 2939–2941. [Google Scholar] [CrossRef] [PubMed]
- Razali, K.; Mohd Nasir, M.H.; Othman, N.; Doolaanea, A.A.; Kumar, J.; Nabeel Ibrahim, W.; Mohamed, W.M.Y. Characterization of neurobehavioral pattern in a zebrafish 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model: A 96-hour behavioral study. PLoS ONE 2022, 17, e0274844. [Google Scholar] [CrossRef] [PubMed]
- Anichtchik, O.; Diekmann, H.; Fleming, A.; Roach, A.; Goldsmith, P.; Rubinsztein, D.C. Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. J. Neurosci. 2008, 28, 8199–8207. [Google Scholar] [CrossRef] [PubMed]
- Xi, Y.; Ryan, J.; Noble, S.; Yu, M.; Yilbas, A.E.; Ekker, M. Impaired dopaminergic neuron development and locomotor function in zebrafish with loss of pink1 function. Eur. J. Neurosci. 2010, 31, 623–633. [Google Scholar] [CrossRef] [PubMed]
- Liu, C.X.; Li, C.Y.; Hu, C.C.; Wang, Y.; Lin, J.; Jiang, Y.H.; Li, Q.; Xu, X. CRISPR/Cas9-induced shank3b mutant zebrafish display autism-like behaviors. Mol. Autism 2018, 9, 23. [Google Scholar] [CrossRef] [PubMed]
- Vaz, R.; Hofmeister, W.; Lindstrand, A. Zebrafish Models of Neurodevelopmental Disorders: Limitations and Benefits of Current Tools and Techniques. Int. J. Mol. Sci. 2019, 20, 1296. [Google Scholar] [CrossRef] [PubMed]
- Stewart, A.M.; Braubach, O.; Spitsbergen, J.; Gerlai, R.; Kalueff, A.V. Zebrafish models for translational neuroscience research: From tank to bedside. Trends Neurosci. 2014, 37, 264–278. [Google Scholar] [CrossRef] [PubMed]
- Teame, T.; Zhang, Z.; Ran, C.; Zhang, H.; Yang, Y.; Ding, Q.; Xie, M.; Gao, C.; Ye, Y.; Duan, M.; et al. The use of zebrafish (Danio rerio) as biomedical models. Anim. Front. 2019, 9, 68–77. [Google Scholar] [CrossRef] [PubMed]
- Giusti, A.; Nguyen, X.B.; Kislyuk, S.; Mignot, M.; Ranieri, C.; Nicolai, J.; Oorts, M.; Wu, X.; Annaert, P.; De Croze, N.; et al. Safety Assessment of Compounds after In Vitro Metabolic Conversion Using Zebrafish Eleuthero Embryos. Int. J. Mol. Sci. 2019, 20, 1712. [Google Scholar] [CrossRef]
- Lu, J.; Peatman, E.; Tang, H.; Lewis, J.; Liu, Z. Profiling of gene duplication patterns of sequenced teleost genomes: Evidence for rapid lineage-specific genome expansion mediated by recent tandem duplications. BMC Genom. 2012, 13, 246. [Google Scholar] [CrossRef] [PubMed]
- Adhish, M.; Manjubala, I. Effectiveness of zebrafish models in understanding human diseases-A review of models. Heliyon 2023, 9, e14557. [Google Scholar] [CrossRef] [PubMed]
- Meyer, B.M.; Froehlich, J.M.; Galt, N.J.; Biga, P.R. Inbred strains of zebrafish exhibit variation in growth performance and myostatin expression following fasting. Comp. Biochem. Physiol. Part A Mol. Integr. Physiol. 2013, 164, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Kalueff, A.V.; Stewart, A.M.; Gerlai, R. Zebrafish as an emerging model for studying complex brain disorders. Trends Pharmacol. Sci. 2014, 35, 63–75. [Google Scholar] [CrossRef]
- Crim, M.J.; Lawrence, C. A fish is not a mouse: Understanding differences in background genetics is critical for reproducibility. Lab. Anim. 2021, 50, 19–25. [Google Scholar] [CrossRef]
- Bashirzade, A.A.; Zabegalov, K.N.; Volgin, A.D.; Belova, A.S.; Demin, K.A.; de Abreu, M.S.; Babchenko, V.Y.; Bashirzade, K.A.; Yenkoyan, K.B.; Tikhonova, M.A.; et al. Modeling neurodegenerative disorders in zebrafish. Neurosci. Biobehav. Rev. 2022, 138, 104679. [Google Scholar] [CrossRef]
- Best, J.D.; Alderton, W.K. Zebrafish: An in vivo model for the study of neurological diseases. Neuropsychiatr. Dis. Treat. 2008, 4, 567–576. [Google Scholar] [CrossRef] [PubMed]
- Dawson, T.M.; Golde, T.E.; Lagier-Tourenne, C. Animal models of neurodegenerative diseases. Nat. Neurosci. 2018, 21, 1370–1379. [Google Scholar] [CrossRef]
- Marin-Moreno, A.; Canoyra, S.; Fernandez-Borges, N.; Espinosa, J.C.; Torres, J.M. Transgenic Mouse Models for the Study of Neurodegenerative Diseases. Front. Biosci. 2023, 28, 21. [Google Scholar] [CrossRef] [PubMed]
- Sakai, C.; Ijaz, S.; Hoffman, E.J. Zebrafish Models of Neurodevelopmental Disorders: Past, Present, and Future. Front. Mol. Neurosci. 2018, 11, 294. [Google Scholar] [CrossRef]
- Tello, J.A.; Williams, H.E.; Eppler, R.M.; Steinhilb, M.L.; Khanna, M. Animal Models of Neurodegenerative Disease: Recent Advances in Fly Highlight Innovative Approaches to Drug Discovery. Front. Mol. Neurosci. 2022, 15, 883358. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Cao, H. Zebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases. Int. J. Mol. Sci. 2021, 22, 10766. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Zhang, J.B.; He, K.J.; Wang, F.; Liu, C.F. Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery. Front. Pharmacol. 2021, 12, 713963. [Google Scholar] [CrossRef] [PubMed]
- Saleem, S.; Kannan, R.R. Zebrafish: A Potential Preclinical Model for Neurological Research in Modern Biology. In Zebrafish Model for Biomedical Research; Bhandari, P.R., Bharani, K.K., Khurana, A., Eds.; Springer Nature Singapore: Singapore, 2022; pp. 321–345. [Google Scholar]
- Mahul-Mellier, A.L.; Burtscher, J.; Maharjan, N.; Weerens, L.; Croisier, M.; Kuttler, F.; Leleu, M.; Knott, G.W.; Lashuel, H.A. The process of Lewy body formation, rather than simply alpha-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc. Natl. Acad. Sci. USA 2020, 117, 4971–4982. [Google Scholar] [CrossRef] [PubMed]
- Robea, M.A.; Balmus, I.M.; Ciobica, A.; Strungaru, S.; Plavan, G.; Gorgan, L.D.; Savuca, A.; Nicoara, M. Parkinson’s Disease-Induced Zebrafish Models: Focussing on Oxidative Stress Implications and Sleep Processes. Oxidative Med. Cell. Longev. 2020, 2020, 1370837. [Google Scholar] [CrossRef] [PubMed]
- Toni, M.; Cioni, C. Fish Synucleins: An Update. Mar. Drugs 2015, 13, 6665–6686. [Google Scholar] [CrossRef] [PubMed]
- Vaz, R.L.; Outeiro, T.F.; Ferreira, J.J. Zebrafish as an Animal Model for Drug Discovery in Parkinson’s Disease and Other Movement Disorders: A Systematic Review. Front. Neurol. 2018, 9, 347. [Google Scholar] [CrossRef] [PubMed]
- Benavides, F.; Rülicke, T.; Prins, J.-B.; Bussell, J.; Scavizzi, F.; Cinelli, P.; Herault, Y.; Wedekind, D. Genetic quality assurance and genetic monitoring of laboratory mice and rats: FELASA Working Group Report. Lab. Anim. 2020, 54, 135–148. [Google Scholar] [CrossRef] [PubMed]
- Bryda, E.C.; Riley, L.K. Multiplex microsatellite marker panels for genetic monitoring of common rat strains. J. Am. Assoc. Lab. Anim. Sci. 2008, 47, 37–41. [Google Scholar] [PubMed]
- Fahey, J.R.; Katoh, H.; Malcolm, R.; Perez, A.V. The case for genetic monitoring of mice and rats used in biomedical research. Mamm. Genome 2013, 24, 89–94. [Google Scholar] [CrossRef] [PubMed]
- Bornemann, K.D.; Staufenbiel, M. Transgenic Mouse Models of Alzheimer’s Disease. Ann. N. Y. Acad. Sci. 2000, 908, 260–266. [Google Scholar] [CrossRef] [PubMed]
- Mullan, M.; Crawford, F.; Axelman, K.; Houlden, H.; Lilius, L.; Winblad, B.; Lannfelt, L. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N–terminus of beta–amyloid. Nat. Genet. 1992, 1, 345–347. [Google Scholar] [CrossRef]
- Stalder, M.; Phinney, A.; Probst, A.; Sommer, B.; Staufenbiel, M.; Jucker, M. Association of Microglia with Amyloid Plaques in Brains of APP23 Transgenic Mice. Am. J. Pathol. 1999, 154, 1673–1684. [Google Scholar] [CrossRef]
- Sturchler-Pierrat, C.; Abramowski, D.; Duke, M.; Wiederhold, K.-H.; Mistl, C.; Rothacher, S.; Ledermann, B.; Bürki, K.; Frey, P.; Paganetti, P.A.; et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 1997, 94, 13287–13292. [Google Scholar] [CrossRef]
- Sturchler-Pierrat, C.; Staufenbiel, M. Pathogenic Mechanisms of Alzheimer’s Disease Analyzed in the APP23 Transgenic Mouse Model. Ann. N. Y. Acad. Sci. 2000, 920, 134–139. [Google Scholar] [CrossRef]
- Jebelli, J.; Hooper, C.; Pocock, J.M. Microglial p53 activation is detrimental to neuronal synapses during activation-induced inflammation: Implications for neurodegeneration. Neurosci. Lett. 2014, 583, 92–97. [Google Scholar] [CrossRef]
- Saito, T.; Saido, T.C. Neuroinflammation in mouse models of Alzheimer’s disease. Clin. Exp. Neuroimmunol. 2018, 9, 211–218. [Google Scholar] [CrossRef] [PubMed]
- Bhattarai, P.; Thomas, A.K.; Zhang, Y.; Kizil, C. The effects of aging on Amyloid-β42-induced neurodegeneration and regeneration in adult zebrafish brain. Neurogenesis 2017, 4, e1322666. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y. Zebrafish as a Model Organism for Studying Pathologic Mechanisms of Neurodegenerative Diseases and other Neural Disorders. Cell. Mol. Neurobiol. 2023, 43, 2603–2620. [Google Scholar] [CrossRef]
- Engelhardt, B. Development of the blood-brain barrier. Cell Tissue Res. 2003, 314, 119–129. [Google Scholar] [CrossRef]
- Daneman, R.; Zhou, L.; Kebede, A.A.; Barres, B.A. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010, 468, 562–566. [Google Scholar] [CrossRef]
- Xie, J.; Farage, E.; Sugimoto, M.; Anand-Apte, B. A novel transgenic zebrafish model for blood-brain and blood-retinal barrier development. BMC Dev. Biol. 2010, 10, 76. [Google Scholar] [CrossRef] [PubMed]
- Fleming, A.; Diekmann, H.; Goldsmith, P. Functional characterisation of the maturation of the blood-brain barrier in larval zebrafish. PLoS ONE 2013, 8, e77548. [Google Scholar] [CrossRef]
- Herschkowitz, N.; Kagan, J.; Zilles, K. Neurobiological bases of behavioral development in the first year. Neuropediatrics 1997, 28, 296–306. [Google Scholar] [CrossRef] [PubMed]
- Prins, M.L.; Hovda, D.A. Developing experimental models to address traumatic brain injury in children. J. Neurotrauma 2003, 20, 123–137. [Google Scholar] [CrossRef] [PubMed]
- Clancy, B.; Kersh, B.; Hyde, J.; Darlington, R.B.; Anand, K.J.; Finlay, B.L. Web-based method for translating neurodevelopment from laboratory species to humans. Neuroinformatics 2007, 5, 79–94. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, R.; Strahle, U.; Scholpp, S. Neurogenesis in zebrafish—From embryo to adult. Neural Dev. 2013, 8, 3. [Google Scholar] [CrossRef]
- Huttenlocher, P.R. Synaptic density in human frontal cortex—Developmental changes and effects of aging. Brain Res. 1979, 163, 195–205. [Google Scholar]
- Micheva, K.D.; Beaulieu, C. Quantitative aspects of synaptogenesis in the rat barrel field cortex with special reference to GABA circuitry. J. Comp. Neurol. 1996, 373, 340–354. [Google Scholar] [CrossRef]
- Drzewiecki, C.M.; Willing, J.; Juraska, J.M. Synaptic number changes in the medial prefrontal cortex across adolescence in male and female rats: A role for pubertal onset. Synapse 2016, 70, 361–368. [Google Scholar] [CrossRef]
- Boulanger-Weill, J.; Candat, V.; Jouary, A.; Romano, S.A.; Perez-Schuster, V.; Sumbre, G. Functional Interactions between Newborn and Mature Neurons Leading to Integration into Established Neuronal Circuits. Curr. Biol. 2017, 27, 1707–1720.e5. [Google Scholar] [CrossRef] [PubMed]
- Chen, R.; Blosser, T.R.; Djekidel, M.N.; Hao, J.; Bhattacherjee, A.; Chen, W.; Tuesta, L.M.; Zhuang, X.; Zhang, Y. Decoding molecular and cellular heterogeneity of mouse nucleus accumbens. Nat. Neurosci. 2021, 24, 1757–1771. [Google Scholar] [CrossRef]
- Schmechel, D.E.; Rakic, P. Arrested proliferation of radial glial cells during midgestation in rhesus monkey. Nature 1979, 277, 303–305. [Google Scholar] [CrossRef]
- deAzevedo, L.C.; Fallet, C.; Moura-Neto, V.; Daumas-Duport, C.; Hedin-Pereira, C.; Lent, R. Cortical radial glial cells in human fetuses: Depth-correlated transformation into astrocytes. J. Neurobiol. 2003, 55, 288–298. [Google Scholar] [CrossRef] [PubMed]
- Jakovcevski, I.; Filipovic, R.; Mo, Z.; Rakic, S.; Zecevic, N. Oligodendrocyte development and the onset of myelination in the human fetal brain. Front. Neuroanat. 2009, 3, 5. [Google Scholar] [CrossRef]
- Ackerman, S.D.; Monk, K.R. The scales and tales of myelination: Using zebrafish and mouse to study myelinating glia. Brain Res. 2016, 1641 Pt A, 79–91. [Google Scholar] [CrossRef]
- Nishiyama, A.; Shimizu, T.; Sherafat, A.; Richardson, W.D. Life-long oligodendrocyte development and plasticity. Semin. Cell Dev. Biol. 2021, 116, 25–37. [Google Scholar] [CrossRef] [PubMed]
- Bin, J.M.; Lyons, D.A. Imaging Myelination In Vivo Using Transparent Animal Models. Brain Plast. 2016, 2, 3–29. [Google Scholar] [CrossRef] [PubMed]
- Schroeder, P.G.; Sneddon, L.U. Exploring the efficacy of immersion analgesics in zebrafish using an integrative approach. Appl. Anim. Behav. Sci. 2017, 187, 93–102. [Google Scholar] [CrossRef]
- Knudsen Dal, N.J.; Speth, M.; Johann, K.; Barz, M.; Beauvineau, C.; Wohlmann, J.; Fenaroli, F.; Gicquel, B.; Griffiths, G.; Alonso-Rodriguez, N. The zebrafish embryo as an in vivo model for screening nanoparticle-formulated lipophilic anti-tuberculosis compounds. Dis. Model Mech. 2022, 15, dmm049147. [Google Scholar] [CrossRef]
- Cassar, S.; Adatto, I.; Freeman, J.L.; Gamse, J.T.; Iturria, I.; Lawrence, C.; Muriana, A.; Peterson, R.T.; Van Cruchten, S.; Zon, L.I. Use of Zebrafish in Drug Discovery Toxicology. Chem. Res. Toxicol. 2020, 33, 95–118. [Google Scholar] [CrossRef]
- Rubinstein, A.L. Zebrafish assays for drug toxicity screening. Expert Opin. Drug Metab. Toxicol. 2006, 2, 231–240. [Google Scholar] [CrossRef]
- Guarin, M.; Faelens, R.; Giusti, A.; De Croze, N.; Leonard, M.; Cabooter, D.; Annaert, P.; de Witte, P.; Ny, A. Spatiotemporal imaging and pharmacokinetics of fluorescent compounds in zebrafish eleuthero-embryos after different routes of administration. Sci. Rep. 2021, 11, 12229. [Google Scholar] [CrossRef]
- de Koning, C.; Beekhuijzen, M.; Tobor-Kaplon, M.; de Vries-Buitenweg, S.; Schoutsen, D.; Leeijen, N.; van de Waart, B.; Emmen, H. Visualizing Compound Distribution during Zebrafish Embryo Development: The Effects of Lipophilicity and DMSO. Birth Defects Res. Part B Dev. Reprod. Toxicol. 2015, 104, 253–272. [Google Scholar] [CrossRef]
- Paul, I.; Tsang, B.; Gerlai, R. Short Exposure to Moderate Concentration of Alcohol During Embryonic Development Does Not Alter Gross Morphology in Zebrafish. Zebrafish 2020, 17, 253–260. [Google Scholar] [CrossRef] [PubMed]
- Rosen, J.N.; Sweeney, M.F.; Mably, J.D. Microinjection of zebrafish embryos to analyze gene function. J. Vis. Exp. 2009, 25, e1115. [Google Scholar]
- Batista-Filho, J.; Falcao, M.A.P.; Maleski, A.L.A.; Soares, A.B.S.; Balan-Lima, L.; Disner, G.R.; Lima, C.; Lopes-Ferreira, M. Early preclinical screening using zebrafish (Danio rerio) reveals the safety of the candidate anti-inflammatory therapeutic agent TnP. Toxicol. Rep. 2021, 8, 13–22. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.C.; Lin, C.Y.; Tsai, H.J. Zebrafish, an In Vivo Platform to Screen Drugs and Proteins for Biomedical Use. Pharmaceuticals 2021, 14, 500. [Google Scholar] [CrossRef]
- Zhu, J.J.; Xu, Y.Q.; He, J.H.; Yu, H.P.; Huang, C.J.; Gao, J.M.; Dong, Q.X.; Xuan, Y.X.; Li, C.Q. Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish. J. Appl. Toxicol. 2014, 34, 139–148. [Google Scholar] [CrossRef]
- Chaoul, V.; Awad, M.; Harb, F.; Najjar, F.; Hamade, A.; Nabout, R.; Soueid, J. Saffron Extract Attenuates Anxiogenic Effect and Improves Cognitive Behavior in an Adult Zebrafish Model of Traumatic Brain Injury. Int. J. Mol. Sci. 2022, 23, 11600. [Google Scholar] [CrossRef]
- Zhao, Y.; Sun, H.; Sha, X.; Gu, L.; Zhan, Z.; Li, W.J. A Review of Automated Microinjection of Zebrafish Embryos. Micromachines 2018, 10, 7. [Google Scholar] [CrossRef]
- Kulkarni, P.; Chaudhari, G.H.; Sripuram, V.; Banote, R.K.; Kirla, K.T.; Sultana, R.; Rao, P.; Oruganti, S.; Chatti, K. Oral dosing in adult zebrafish: Proof-of-concept using pharmacokinetics and pharmacological evaluation of carbamazepine. Pharmacol. Rep. 2014, 66, 179–183. [Google Scholar] [CrossRef]
- Arjun, P.; Freeman, J.L.; Kannan, R.R. Neurospecific fabrication and toxicity assessment of a PNIPAM nanogel encapsulated with trans-tephrostachin for blood-brain-barrier permeability in zebrafish model. Heliyon 2022, 8, e10237. [Google Scholar] [CrossRef]
- Lin, H.S.; Huang, Y.L.; Wang, Y.S.; Hsiao, E.; Hsu, T.A.; Shiao, H.Y.; Jiaang, W.T.; Sampurna, B.P.; Lin, K.H.; Wu, M.S.; et al. Identification of Novel Anti-Liver Cancer Small Molecules with Better Therapeutic Index than Sorafenib via Zebrafish Drug Screening Platform. Cancers 2019, 11, 739. [Google Scholar] [CrossRef]
- Ochocki, A.J.; Kenney, J.W. A gelatin-based feed for precise and non-invasive drug delivery to adult zebrafish. J. Exp. Biol. 2023, 226, jeb245186. [Google Scholar] [CrossRef] [PubMed]
- Lu, Y.; Patton, E.E. Long-term non-invasive drug treatments in adult zebrafish that lead to melanoma drug resistance. Dis. Model Mech. 2022, 15, dmm049401. [Google Scholar] [CrossRef] [PubMed]
- Dang, M.; Fogley, R.; Zon, L.I. Identifying Novel Cancer Therapies Using Chemical Genetics and Zebrafish. Adv. Exp. Med. Biol. 2016, 916, 103–124. [Google Scholar] [PubMed]
- Zang, L.; Morikane, D.; Shimada, Y.; Tanaka, T.; Nishimura, N. A novel protocol for the oral administration of test chemicals to adult zebrafish. Zebrafish 2011, 8, 203–210. [Google Scholar] [CrossRef]
- Goldsmith, J.R.; Cocchiaro, J.L.; Rawls, J.F.; Jobin, C. Glafenine-induced intestinal injury in zebrafish is ameliorated by mu-opioid signaling via enhancement of Atf6-dependent cellular stress responses. Dis. Model Mech. 2013, 6, 146–159. [Google Scholar] [PubMed]
- Canadian Council on Animal Care. Guidelines on: The Care and Use of Fish in Research, Teaching and Testing; Canadian Council on Animal Care, Ed.; CCAC: Ottawa, ON, Canada, 2005. [Google Scholar]
- Harper, C.; Lawrence, C. The Laboratory Zebrafish; CRC Press: Boca Raton, FL, USA, 2011. [Google Scholar]
- Dayal, N.; Thakur, M.; Soparkar, A.; Doktor, M.; Patil, P.; Joshi, D.S. Effective Method to Deliver Test Substance in Adult Zebrafish (Danio rerio). Int. J. Adv. Res. 2016, 4, 543–551. [Google Scholar] [CrossRef] [PubMed]
- Cocchiaro, J.L.; Rawls, J.F. Microgavage of zebrafish larvae. J. Vis. Exp. 2013, 72, e4434. [Google Scholar]
- Dang, M.; Henderson, R.E.; Garraway, L.A.; Zon, L.I. Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies. Dis. Model Mech. 2016, 9, 811–820. [Google Scholar] [CrossRef] [PubMed]
- Magno, L.D.; Fontes, A.; Goncalves, B.M.; Gouveia, A., Jr. Pharmacological study of the light/dark preference test in zebrafish (Danio rerio): Waterborne administration. Pharmacol. Biochem. Behav. 2015, 135, 169–176. [Google Scholar] [CrossRef]
- Collymore, C.; Rasmussen, S.; Tolwani, R.J. Gavaging adult zebrafish. J. Vis. Exp. 2013, 78, e50691. [Google Scholar]
- Wong, D.; von Keyserlingk, M.A.; Richards, J.G.; Weary, D.M. Conditioned place avoidance of zebrafish (Danio rerio) to three chemicals used for euthanasia and anaesthesia. PLoS ONE 2014, 9, e88030. [Google Scholar] [CrossRef] [PubMed]
- Martins, T.; Valentim, A.M.; Pereira, N.; Antunes, L.M. Anaesthesia and analgesia in laboratory adult zebrafish: A question of refinement. Lab. Anim. 2016, 50, 476–488. [Google Scholar] [CrossRef] [PubMed]
- Readman, G.D.; Owen, S.F.; Murrell, J.C.; Knowles, T.G. Do fish perceive anaesthetics as aversive? PLoS ONE 2013, 8, e73773. [Google Scholar] [CrossRef] [PubMed]
- Wilson, J.M.; Bunte, R.M.; Carty, A.J. Evaluation of rapid cooling and tricaine methanesulfonate (MS222) as methods of euthanasia in zebrafish (Danio rerio). J. Am. Assoc. Lab. Anim. Sci. 2009, 48, 785–789. [Google Scholar]
- Macova, S.; Dolezelova, P.; Pistekova, V.; Svobodova, Z.; Bedanova, I.; Voslarova, E. Comparison of acute toxicity of 2-phenoxyethanol and clove oil to juvenile and embryonic stages of Danio rerio. Neuro. Endocrinol. Lett. 2008, 29, 680–684. [Google Scholar]
- Brockschmidt, A.; Filippi, A.; Charbel Issa, P.; Nelles, M.; Urbach, H.; Eter, N.; Driever, W.; Weber, R.G. Neurologic and ocular phenotype in Pitt-Hopkins syndrome and a zebrafish model. Hum. Genet. 2011, 130, 645–655. [Google Scholar] [CrossRef] [PubMed]
- Lu, S.; Lyu, Z.; Wang, Z.; Kou, Y.; Liu, C.; Li, S.; Hu, M.; Zhu, H.; Wang, W.; Zhang, C.; et al. Lipin 1 deficiency causes adult-onset myasthenia with motor neuron dysfunction in humans and neuromuscular junction defects in zebrafish. Theranostics 2021, 11, 2788–2805. [Google Scholar] [CrossRef]
- Espino-Saldana, A.E.; Rodriguez-Ortiz, R.; Pereida-Jaramillo, E.; Martinez-Torres, A. Modeling Neuronal Diseases in Zebrafish in the Era of CRISPR. Curr. Neuropharmacol. 2020, 18, 136–152. [Google Scholar] [CrossRef]
- Corey, D.R.; Abrams, J.M. Morpholino antisense oligonucleotides: Tools for investigating vertebrate development. Genome Biol. 2001, 2, REVIEWS1015. [Google Scholar] [CrossRef]
- Moulton, J.D.; Yan, Y.L. Using Morpholinos to control gene expression. Curr. Protoc. Mol. Biol. 2008, 83, 26.8. 1–26.8. 29. [Google Scholar] [CrossRef]
- Scoles, D.R.; Minikel, E.V.; Pulst, S.M. Antisense oligonucleotides: A primer. Neurol. Genet. 2019, 5, e323. [Google Scholar] [CrossRef]
- Rea, V.; Van Raay, T.J. Using Zebrafish to Model Autism Spectrum Disorder: A Comparison of ASD Risk Genes Between Zebrafish and Their Mammalian Counterparts. Front. Mol. Neurosci. 2020, 13, 575575. [Google Scholar] [CrossRef] [PubMed]
- Wager, K.; Zdebik, A.A.; Fu, S.; Cooper, J.D.; Harvey, R.J.; Russell, C. Neurodegeneration and Epilepsy in a Zebrafish Model of CLN3 Disease (Batten Disease). PLoS ONE 2016, 11, e0157365. [Google Scholar] [CrossRef] [PubMed]
- Roberts, T.C.; Langer, R.; Wood, M.J.A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 2020, 19, 673–694. [Google Scholar] [CrossRef] [PubMed]
- Doudna, J.A.; Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014, 346, 1258096. [Google Scholar] [CrossRef]
- Khalil, A.M. The genome editing revolution: Review. J. Genet. Eng. Biotechnol. 2020, 18, 68. [Google Scholar] [CrossRef]
- Adli, M. The CRISPR tool kit for genome editing and beyond. Nat. Commun. 2018, 9, 1911. [Google Scholar] [CrossRef]
- Arroyo-Olarte, R.D.; Bravo Rodriguez, R.; Morales-Rios, E. Genome Editing in Bacteria: CRISPR-Cas and Beyond. Microorganisms 2021, 9, 844. [Google Scholar] [CrossRef]
- Asmamaw, M.; Zawdie, B. Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing. Biologics 2021, 15, 353–361. [Google Scholar] [PubMed]
- Rees, H.A.; Komor, A.C.; Yeh, W.H.; Caetano-Lopes, J.; Warman, M.; Edge, A.S.B.; Liu, D.R. Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat. Commun. 2017, 8, 15790. [Google Scholar] [CrossRef] [PubMed]
- Bai, H.; Liu, L.; An, K.; Lu, X.; Harrison, M.; Zhao, Y.; Yan, R.; Lu, Z.; Li, S.; Lin, S.; et al. CRISPR/Cas9-mediated precise genome modification by a long ssDNA template in zebrafish. BMC Genom. 2020, 21, 67. [Google Scholar] [CrossRef] [PubMed]
- Irion, U.; Krauss, J.; Nusslein-Volhard, C. Precise and efficient genome editing in zebrafish using the CRISPR/Cas9 system. Development 2014, 141, 4827–4830. [Google Scholar] [CrossRef] [PubMed]
- Hwang, W.Y.; Fu, Y.; Reyon, D.; Maeder, M.L.; Kaini, P.; Sander, J.D.; Joung, J.K.; Peterson, R.T.; Yeh, J.R. Heritable and precise zebrafish genome editing using a CRISPR-Cas system. PLoS ONE 2013, 8, e68708. [Google Scholar] [CrossRef]
- Schellens, R.; de Vrieze, E.; Graave, P.; Broekman, S.; Nagel-Wolfrum, K.; Peters, T.; Kremer, H.; Collin, R.W.J.; van Wijk, E. Zebrafish as a Model to Evaluate a CRISPR/Cas9-Based Exon Excision Approach as a Future Treatment Option for EYS-Associated Retinitis Pigmentosa. Int. J. Mol. Sci. 2021, 22, 9154. [Google Scholar] [CrossRef] [PubMed]
- Rasul, M.F.; Hussen, B.M.; Salihi, A.; Ismael, B.S.; Jalal, P.J.; Zanichelli, A.; Jamali, E.; Baniahmad, A.; Ghafouri-Fard, S.; Basiri, A.; et al. Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. Mol. Cancer 2022, 21, 64. [Google Scholar] [CrossRef]
- Saleem, S.; Kannan, R.R. Zebrafish: A Promising Real-Time Model System for Nanotechnology-Mediated Neurospecific Drug Delivery. Nanoscale Res. Lett. 2021, 16, 135. [Google Scholar] [CrossRef] [PubMed]
- Andrikopoulos, N.; Song, Z.; Wan, X.; Douek, A.M.; Javed, I.; Fu, C.; Xing, Y.; Xin, F.; Li, Y.; Kakinen, A.; et al. Inhibition of Amyloid Aggregation and Toxicity with Janus Iron Oxide Nanoparticles. Chem. Mater. 2021, 33, 6484–6500. [Google Scholar] [CrossRef]
- Xiong, S.; Liu, W.; Zhou, Y.; Mo, Y.; Liu, Y.; Chen, X.; Pan, H.; Yuan, D.; Wang, Q.; Chen, T. Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation. Asian J. Pharm. Sci. 2020, 15, 518–528. [Google Scholar] [CrossRef]
- Rabanel, J.M.; Piec, P.A.; Landri, S.; Patten, S.A.; Ramassamy, C. Transport of PEGylated-PLA nanoparticles across a blood brain barrier model, entry into neuronal cells and in vivo brain bioavailability. J. Control. Release 2020, 328, 679–695. [Google Scholar] [CrossRef]
- Patton, C.; FarrIII, G.H.; An, D.; Martini, P.G.V.; Maves, L. Lipid Nanoparticle Packaging Is an Effective and Nontoxic mRNA Delivery Platform in Embryonic Zebrafish. Zebrafish 2018, 15, 217–227. [Google Scholar] [CrossRef]
- Kalaiarasi, S.; Arjun, P.; Nandhagopal, S.; Brijitta, J.; Iniyan, M.A.; Vincent, P.S.G.; Kannan, R.R. Development of biocompatible nanogel for sustained drug release by overcoming the blood brain barrier in zebrafish model. J. Appl. Biomed. 2016, 14, 157–169. [Google Scholar] [CrossRef]
- Sieber, S.; Grossen, P.; Bussmann, J.; Campbell, F.; Kros, A.; Witzigmann, D.; Huwyler, J. Zebrafish as a preclinical in vivo screening model for nanomedicines. Adv. Drug Deliv. Rev. 2019, 151–152, 152–168. [Google Scholar] [CrossRef]
- Patra, J.K.; Das, G.; Fraceto, L.F.; Campos, E.V.R.; Rodriguez-Torres, M.D.P.; Acosta-Torres, L.S.; Diaz-Torres, L.A.; Grillo, R.; Swamy, M.K.; Sharma, S.; et al. Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnology 2018, 16, 71. [Google Scholar] [CrossRef] [PubMed]
- Wu, D.; Chen, Q.; Chen, X.; Han, F.; Chen, Z.; Wang, Y. The blood-brain barrier: Structure, regulation, and drug delivery. Signal Transduct. Target. Ther. 2023, 8, 217. [Google Scholar] [CrossRef] [PubMed]
- Igartúa, D.E.; Martinez, C.S.; Temprana, C.F.; Alonso, S.d.V.; Prieto, M.J. PAMAM dendrimers as a carbamazepine delivery system for neurodegenerative diseases: A biophysical and nanotoxicological characterization. Int. J. Pharm. 2018, 544, 191–202. [Google Scholar] [CrossRef]
- Nazaruk, E.; Majkowska-Pilip, A.; Bilewicz, R. Lipidic Cubic-Phase Nanoparticles-Cubosomes for Efficient Drug Delivery to Cancer Cells. Chempluschem 2017, 82, 570–575. [Google Scholar] [CrossRef]
- Barriga, H.M.G.; Holme, M.N.; Stevens, M.M. Cubosomes: The Next Generation of Smart Lipid Nanoparticles? Angew. Chem. Int. Ed. Engl. 2019, 58, 2958–2978. [Google Scholar] [CrossRef]
- Azhari, H.; Younus, M.; Hook, S.M.; Boyd, B.J.; Rizwan, S.B. Cubosomes enhance drug permeability across the blood-brain barrier in zebrafish. Int. J. Pharm. 2021, 600, 120411. [Google Scholar] [CrossRef]
- Sun, M.; Cao, Y.; Sun, Q.; Ren, X.; Hu, J.; Sun, Z.; Duan, J. Exposure to polydopamine nanoparticles induces neurotoxicity in the developing zebrafish. NanoImpact 2021, 24, 100353. [Google Scholar] [CrossRef] [PubMed]
- da Rocha, A.M.; Kist, L.W.; Almeida, E.A.; Silva, D.G.H.; Bonan, C.D.; Altenhofen, S.; Kaufmann, C.G., Jr.; Bogo, M.R.; Barros, D.M.; Oliveira, S.; et al. Neurotoxicity in zebrafish exposed to carbon nanotubes: Effects on neurotransmitters levels and antioxidant system. Comp. Biochem. Physiol. Part C Toxicol. Pharmacol. 2019, 218, 30–35. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Liu, B.; Li, X.L.; Li, Y.X.; Sun, M.Z.; Chen, D.Y.; Zhao, X.; Feng, X.Z. SiO2 nanoparticles change colour preference and cause Parkinson’s-like behaviour in zebrafish. Sci. Rep. 2014, 4, 3810. [Google Scholar] [CrossRef] [PubMed]
- Sheng, L.; Wang, L.; Su, M.; Zhao, X.; Hu, R.; Yu, X.; Hong, J.; Liu, D.; Xu, B.; Zhu, Y.; et al. Mechanism of TiO2 nanoparticle-induced neurotoxicity in zebrafish (Danio rerio). Environ. Toxicol. 2016, 31, 163–175. [Google Scholar] [CrossRef]
- Ren, C.; Hu, X.; Li, X.; Zhou, Q. Ultra-trace graphene oxide in a water environment triggers Parkinson’s disease-like symptoms and metabolic disturbance in zebrafish larvae. Biomaterials 2016, 93, 83–94. [Google Scholar] [CrossRef]
- Johnston, H.J.; Verdon, R.; Gillies, S.; Brown, D.M.; Fernandes, T.F.; Henry, T.B.; Rossi, A.G.; Tran, L.; Tucker, C.; Tyler, C.R.; et al. Adoption of in vitro systems and zebrafish embryos as alternative models for reducing rodent use in assessments of immunological and oxidative stress responses to nanomaterials. Crit. Rev. Toxicol. 2018, 48, 252–271. [Google Scholar] [CrossRef] [PubMed]
- Krishnaraj, C.; Harper, S.L.; Yun, S.I. In Vivo toxicological assessment of biologically synthesized silver nanoparticles in adult Zebrafish (Danio rerio). J. Hazard. Mater. 2016, 301, 480–491. [Google Scholar] [CrossRef] [PubMed]
- Truong, L.; Tilton, S.C.; Zaikova, T.; Richman, E.; Waters, K.M.; Hutchison, J.E.; Tanguay, R.L. Surface functionalities of gold nanoparticles impact embryonic gene expression responses. Nanotoxicology 2013, 7, 192–201. [Google Scholar] [CrossRef]
- Jia, H.R.; Zhu, Y.X.; Duan, Q.Y.; Chen, Z.; Wu, F.G. Nanomaterials meet zebrafish: Toxicity evaluation and drug delivery applications. J. Control. Release 2019, 311–312, 301–318. [Google Scholar] [CrossRef]
- Corrales-Orovio, R.; Carvajal, F.; Holmes, C.; Miranda, M.; Gonzalez-Itier, S.; Cardenas, C.; Vera, C.; Schenck, T.L.; Egana, J.T. Development of a photosynthetic hydrogel as potential wound dressing for the local delivery of oxygen and bioactive molecules. Acta Biomater. 2023, 155, 154–166. [Google Scholar] [CrossRef]
- Tomic, S.L.; Nikodinovic-Runic, J.; Vukomanovic, M.; Babic, M.M.; Vukovic, J.S. Novel Hydrogel Scaffolds Based on Alginate, Gelatin, 2-Hydroxyethyl Methacrylate, and Hydroxyapatite. Polymers 2021, 13, 932. [Google Scholar] [CrossRef]
- Hasanzadeh, E.; Seifalian, A.; Mellati, A.; Saremi, J.; Asadpour, S.; Enderami, S.E.; Nekounam, H.; Mahmoodi, N. Injectable hydrogels in central nervous system: Unique and novel platforms for promoting extracellular matrix remodeling and tissue engineering. Mater. Today Bio. 2023, 20, 100614. [Google Scholar] [CrossRef]
- Xu, J.; Wong, C.-W.; Hsu, S.-h. An Injectable, Electroconductive Hydrogel/Scaffold for Neural Repair and Motion Sensing. Chem. Mater. 2020, 32, 10407–10422. [Google Scholar] [CrossRef]
- Wang, H.; Zhang, H.; Xie, Z.; Chen, K.; Ma, M.; Huang, Y.; Li, M.; Cai, Z.; Wang, P.; Shen, H. Injectable hydrogels for spinal cord injury repair. Eng. Regen. 2022, 3, 407–419. [Google Scholar] [CrossRef]
- Liang, Y.; He, J.; Guo, B. Functional Hydrogels as Wound Dressing to Enhance Wound Healing. ACS Nano 2021, 15, 12687–12722. [Google Scholar] [CrossRef]
- Firlar, I.; Altunbek, M.; McCarthy, C.; Ramalingam, M.; Camci-Unal, G. Functional Hydrogels for Treatment of Chronic Wounds. Gels 2022, 8, 127. [Google Scholar] [CrossRef] [PubMed]
- Dabiri, G.; Damstetter, E.; Phillips, T. Choosing a Wound Dressing Based on Common Wound Characteristics. Adv. Wound Care 2016, 5, 32–41. [Google Scholar] [CrossRef]
- Cummings, J.L. Alzheimer’s disease. N. Engl. J. Med. 2004, 351, 56–67. [Google Scholar] [CrossRef] [PubMed]
- Eratne, D.; Loi, S.M.; Farrand, S.; Kelso, W.; Velakoulis, D.; Looi, J.C. Alzheimer’s disease: Clinical update on epidemiology, pathophysiology and diagnosis. Australas. Psychiatry 2018, 26, 347–357. [Google Scholar] [CrossRef] [PubMed]
- Lane, C.A.; Hardy, J.; Schott, J.M. Alzheimer’s disease. Eur. J. Neurol. 2018, 25, 59–70. [Google Scholar] [CrossRef] [PubMed]
- Dorszewska, J.; Prendecki, M.; Oczkowska, A.; Dezor, M.; Kozubski, W. Molecular Basis of Familial and Sporadic Alzheimer’s Disease. Curr. Alzheimer Res. 2016, 13, 952–963. [Google Scholar] [CrossRef]
- Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011, 1, a006189. [Google Scholar] [CrossRef]
- Maccioni, R.B.; Farias, G.; Morales, I.; Navarrete, L. The revitalized tau hypothesis on Alzheimer’s disease. Arch Med. Res. 2010, 41, 226–231. [Google Scholar] [CrossRef]
- Ghoshal, N.; Garcia-Sierra, F.; Wuu, J.; Leurgans, S.; Bennett, D.A.; Berry, R.W.; Binder, L.I. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer’s disease. Exp. Neurol. 2002, 177, 475–493. [Google Scholar] [CrossRef]
- Dickson, D.W.; Lin, W.L. Neuronal Inclusions. In Encyclopedia of the Neurological Sciences, 2nd ed.; Aminoff, M.J., Daroff, R.B., Eds.; Academic Press: Oxford, UK, 2014; pp. 441–455. [Google Scholar]
- Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353–356. [Google Scholar] [CrossRef] [PubMed]
- Selkoe, D.J. The molecular pathology of Alzheimer’s disease. Neuron 1991, 6, 487–498. [Google Scholar] [CrossRef]
- Voisin, T.; Vellas, B. Diagnosis and treatment of patients with severe Alzheimer’s disease. Drugs Aging 2009, 26, 135–144. [Google Scholar] [CrossRef] [PubMed]
- Blennow, K.; de Leon, M.J.; Zetterberg, H. Alzheimer’s disease. Lancet 2006, 368, 387–403. [Google Scholar] [CrossRef]
- Nada, S.E.; Williams, F.E.; Shah, Z.A. Development of a Novel and Robust Pharmacological Model of Okadaic Acid-induced Alzheimer’s Disease in Zebrafish. CNS Neurol. Disord. Drug Targets 2016, 15, 86–94. [Google Scholar] [CrossRef] [PubMed]
- He, X.; Zhong, Z.-M.; Che, Y. Locomotor activity and learning and memory abilities in Alzheimer’s disease induced by Aluminum in an acid environment in Zebrafish. Zool. Res. 2012, 2, 231. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.; Huang, C.; Zheng, L.; Simonich, M.; Bai, C.; Tanguay, R.; Dong, Q. Trimethyltin chloride (TMT) neurobehavioral toxicity in embryonic zebrafish. Neurotoxicology Teratol. 2011, 33, 721–726. [Google Scholar] [CrossRef] [PubMed]
- Nery, L.R.; Eltz, N.S.; Hackman, C.; Fonseca, R.; Altenhofen, S.; Guerra, H.N.; Freitas, V.M.; Bonan, C.D.; Vianna, M.R. Brain intraventricular injection of amyloid-beta in zebrafish embryo impairs cognition and increases tau phosphorylation, effects reversed by lithium. PLoS ONE 2014, 9, e105862. [Google Scholar] [CrossRef]
- Rogaeva, E.; Meng, Y.; Lee, J.H.; Gu, Y.; Kawarai, T.; Zou, F.; Katayama, T.; Baldwin, C.T.; Cheng, R.; Hasegawa, H.; et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007, 39, 168–177. [Google Scholar] [CrossRef]
- Joshi, P.; Liang, J.O.; DiMonte, K.; Sullivan, J.; Pimplikar, S.W. Amyloid precursor protein is required for convergent-extension movements during Zebrafish development. Dev. Biol. 2009, 335, 1–11. [Google Scholar] [CrossRef]
- Andersen, O.M.; Reiche, J.; Schmidt, V.; Gotthardt, M.; Spoelgen, R.; Behlke, J.; von Arnim, C.A.; Breiderhoff, T.; Jansen, P.; Wu, X.; et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA 2005, 102, 13461–13466. [Google Scholar] [CrossRef] [PubMed]
- Koehler, D.; Shah, Z.A.; Williams, F.E. The GSK3beta inhibitor, TDZD-8, rescues cognition in a zebrafish model of okadaic acid-induced Alzheimer’s disease. Neurochem. Int. 2019, 122, 31–37. [Google Scholar] [CrossRef] [PubMed]
- Javed, I.; Peng, G.; Xing, Y.; Yu, T.; Zhao, M.; Kakinen, A.; Faridi, A.; Parish, C.L.; Ding, F.; Davis, T.P.; et al. Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy. Nat. Commun. 2019, 10, 3780. [Google Scholar] [CrossRef] [PubMed]
- Yang, J.; Zhang, P.; Hu, Y.; Liu, T.; Sun, J.; Wang, X. Synthesis and biological evaluation of 3-arylcoumarins as potential anti-Alzheimer’s disease agents. J. Enzym. Inhib. Med. Chem. 2019, 34, 651–656. [Google Scholar] [CrossRef] [PubMed]
- Simon, D.K.; Tanner, C.M.; Brundin, P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin. Geriatr. Med. 2020, 36, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Beitz, J.M. Parkinson’s disease: A review. Front Biosci. 2014, 6, 65–74. [Google Scholar] [CrossRef] [PubMed]
- Flinn, L.J.; Keatinge, M.; Bretaud, S.; Mortiboys, H.; Matsui, H.; De Felice, E.; Woodroof, H.I.; Brown, L.; McTighe, A.; Soellner, R.; et al. TigarB causes mitochondrial dysfunction and neuronal loss in PINK1 deficiency. Ann. Neurol. 2013, 74, 837–847. [Google Scholar] [CrossRef]
- Soman, S.; Keatinge, M.; Moein, M.; Da Costa, M.; Mortiboys, H.; Skupin, A.; Sugunan, S.; Bazala, M.; Kuznicki, J.; Bandmann, O. Inhibition of the mitochondrial calcium uniporter rescues dopaminergic neurons in pink1(-/-) zebrafish. Eur. J. Neurosci. 2017, 45, 528–535. [Google Scholar] [CrossRef] [PubMed]
- Nellore, J.; Pauline, C.; Amarnath, K. Bacopa monnieri Phytochemicals Mediated Synthesis of Platinum Nanoparticles and Its Neurorescue Effect on 1-Methyl 4-Phenyl 1,2,3,6 Tetrahydropyridine-Induced Experimental Parkinsonism in Zebrafish. J. Neurodegener. Dis. 2013, 2013, 972391. [Google Scholar] [PubMed]
- Xiong, S.; Liu, W.; Li, D.; Chen, X.; Liu, F.; Yuan, D.; Pan, H.; Wang, Q.; Fang, S.; Chen, T. Oral Delivery of Puerarin Nanocrystals to Improve Brain Accumulation and Anti-Parkinsonian Efficacy. Mol. Pharm. 2019, 16, 1444–1455. [Google Scholar] [CrossRef]
- Chen, T.; Liu, W.; Xiong, S.; Li, D.; Fang, S.; Wu, Z.; Wang, Q.; Chen, X. Nanoparticles Mediating the Sustained Puerarin Release Facilitate Improved Brain Delivery to Treat Parkinson’s Disease. ACS Appl. Mater. Interfaces 2019, 11, 45276–45289. [Google Scholar] [CrossRef] [PubMed]
- Wang, Q.; Ma, R.; Liu, P.; Cheng, G.; Yang, Q.; Chen, X.; Wu, Z.; Yuan, D.; Chen, T. Efficient Sustained-Release Nanoparticle Delivery System Protects Nigral Neurons in a Toxin Model of Parkinson’s Disease. Pharmaceutics 2022, 14, 1731. [Google Scholar] [CrossRef]
- Zhao, Y.; Xiong, S.; Liu, P.; Liu, W.; Wang, Q.; Liu, Y.; Tan, H.; Chen, X.; Shi, X.; Wang, Q.; et al. Polymeric Nanoparticles-Based Brain Delivery with Improved Therapeutic Efficacy of Ginkgolide B in Parkinson’s Disease. Int. J. Nanomed. 2020, 15, 10453–10467. [Google Scholar] [CrossRef]
- Chen, T.; Li, Y.; Li, C.; Yi, X.; Wang, R.; Lee, S.M.; Zheng, Y. Pluronic P85/F68 Micelles of Baicalein Could Interfere with Mitochondria to Overcome MRP2-Mediated Efflux and Offer Improved Anti-Parkinsonian Activity. Mol. Pharm. 2017, 14, 3331–3342. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Zhou, F.; Xu, T.; Song, H.; Lu, B. Acteoside protects against 6-OHDA-induced dopaminergic neuron damage via Nrf2-ARE signaling pathway. Food Chem. Toxicol. 2018, 119, 6–13. [Google Scholar] [CrossRef]
- Benvenutti, R.; Marcon, M.; Reis, C.G.; Nery, L.R.; Miguel, C.; Herrmann, A.P.; Vianna, M.R.M.; Piato, A. N-acetylcysteine protects against motor, optomotor and morphological deficits induced by 6-OHDA in zebrafish larvae. PeerJ 2018, 6, e4957. [Google Scholar] [CrossRef]
- Cronin, A.; Grealy, M. Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson’s Disease. Neuroscience 2017, 367, 34–46. [Google Scholar] [CrossRef]
- Stocchetti, N.; Zanier, E.R. Chronic impact of traumatic brain injury on outcome and quality of life: A narrative review. Crit. Care 2016, 20, 148. [Google Scholar] [CrossRef]
- Prins, M.; Greco, T.; Alexander, D.; Giza, C.C. The pathophysiology of traumatic brain injury at a glance. Dis. Model Mech. 2013, 6, 1307–1315. [Google Scholar] [CrossRef]
- Dewan, M.C.; Rattani, A.; Gupta, S.; Baticulon, R.E.; Hung, Y.C.; Punchak, M.; Agrawal, A.; Adeleye, A.O.; Shrime, M.G.; Rubiano, A.M.; et al. Estimating the global incidence of traumatic brain injury. J. Neurosurg. 2018, 130, 1080–1097. [Google Scholar] [CrossRef]
- Turner, G.M.; McMullan, C.; Aiyegbusi, O.L.; Bem, D.; Marshall, T.; Calvert, M.; Mant, J.; Belli, A. Stroke risk following traumatic brain injury: Systematic review and meta-analysis. Int. J. Stroke 2021, 16, 370–384. [Google Scholar] [CrossRef]
- Chen, Y.H.; Kang, J.H.; Lin, H.C. Patients with traumatic brain injury: Population-based study suggests increased risk of stroke. Stroke 2011, 42, 2733–2739. [Google Scholar] [CrossRef] [PubMed]
- Qu, D.; Li, W.; Zhang, S.; Li, R.; Wang, H.; Chen, B. Traumatic Brain Injury Is Associated With Both Hemorrhagic Stroke and Ischemic Stroke: A Systematic Review and Meta-Analysis. Front. Neurosci. 2022, 16, 814684. [Google Scholar] [CrossRef] [PubMed]
- Paramita, P.; Sethu, S.N.; Subhapradha, N.; Ragavan, V.; Ilangovan, R.; Balakrishnan, A.; Srinivasan, N.; Murugesan, R.; Moorthi, A. Neuro-protective effects of nano-formulated hesperetin in a traumatic brain injury model of Danio rerio. Drug Chem. Toxicol. 2022, 45, 507–514. [Google Scholar] [CrossRef]
- Liu, X.Y.E.; Park, E.; Barretto, T.; Liu, E.; Ferrier, G.A.; Tavakkoli, J.; Baker, A.J. Effect of Human Umbilical Cord Perivascular Cell-Conditioned Media in an Adult Zebrafish Model of Traumatic Brain Injury. Zebrafish 2020, 17, 177–186. [Google Scholar] [CrossRef]
- McCutcheon, V.; Park, E.; Liu, E.; Wang, Y.; Wen, X.Y.; Baker, A.J. A Model of Excitotoxic Brain Injury in Larval Zebrafish: Potential Application for High-Throughput Drug Evaluation to Treat Traumatic Brain Injury. Zebrafish 2016, 13, 161–169. [Google Scholar] [CrossRef]
- Matsumoto, M.; Miyamoto, M.; Sawahata, M.; Izumi, Y.; Takada-Takatori, Y.; Kume, T. Establishing a high throughput drug screening system for cerebral ischemia using zebrafish larvae. J. Pharmacol. Sci. 2021, 147, 138–142. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Wu, H.; Sheng, H.; Wang, Y.; Li, X.; Wang, Y.; Zhao, L. Discovery of anti-stroke active substances in Guhong injection based on multi-phenotypic screening of zebrafish. Biomed. Pharmacother. 2022, 155, 113744. [Google Scholar] [CrossRef]
- Lord, C.; Brugha, T.S.; Charman, T.; Cusack, J.; Dumas, G.; Frazier, T.; Jones, E.J.H.; Jones, R.M.; Pickles, A.; State, M.W.; et al. Autism spectrum disorder. Nat. Rev. Dis. Primers 2020, 6, 5. [Google Scholar] [CrossRef]
- Tayanloo-Beik, A.; Hamidpour, S.K.; Abedi, M.; Shojaei, H.; Tavirani, M.R.; Namazi, N.; Larijani, B.; Arjmand, B. Zebrafish Modeling of Autism Spectrum Disorders, Current Status and Future Prospective. Front. Psychiatry 2022, 13, 911770. [Google Scholar] [CrossRef] [PubMed]
- Modabbernia, A.; Velthorst, E.; Reichenberg, A. Environmental risk factors for autism: An evidence-based review of systematic reviews and meta-analyses. Mol. Autism 2017, 8, 13. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.A.; Chen, Z.J.; Li, X.D.; Gu, M.H.; Xia, N.; Gong, C.; Zhou, Z.W.; Yasin, G.; Xie, H.Y.; Wei, X.P.; et al. Epidemiology of autism spectrum disorders: Global burden of disease 2019 and bibliometric analysis of risk factors. Front. Pediatr. 2022, 10, 972809. [Google Scholar] [CrossRef] [PubMed]
- Meshalkina, D.A.; Kizlyk, M.N.; Kysil, E.V.; Collier, A.D.; Echevarria, D.J.; Abreu, M.S.; Barcellos, L.J.G.; Song, C.; Warnick, J.E.; Kyzar, E.J.; et al. Zebrafish models of autism spectrum disorder. Exp. Neurol. 2018, 299 Pt A, 207–216. [Google Scholar] [CrossRef]
- den Broeder, M.J.; van der Linde, H.; Brouwer, J.R.; Oostra, B.A.; Willemsen, R.; Ketting, R.F. Generation and characterization of FMR1 knockout zebrafish. PLoS ONE 2009, 4, e7910. [Google Scholar] [CrossRef]
- Doldur-Balli, F.; Zimmerman, A.J.; Keenan, B.T.; Shetty, Z.Y.; Grant, S.F.A.; Seiler, C.; Veatch, O.J.; Pack, A.I. Pleiotropic effects of a high confidence Autism Spectrum Disorder gene, arid1b, on zebrafish sleep. Neurobiol. Sleep Circadian Rhythm. 2023, 14, 100096. [Google Scholar] [CrossRef]
- Sugathan, A.; Biagioli, M.; Golzio, C.; Erdin, S.; Blumenthal, I.; Manavalan, P.; Ragavendran, A.; Brand, H.; Lucente, D.; Miles, J.; et al. CHD8 regulates neurodevelopmental pathways associated with autism spectrum disorder in neural progenitors. Proc. Natl. Acad. Sci. USA 2014, 111, E4468–E4477. [Google Scholar] [CrossRef]
- Pietri, T.; Roman, A.C.; Guyon, N.; Romano, S.A.; Washbourne, P.; Moens, C.B.; de Polavieja, G.G.; Sumbre, G. The first mecp2-null zebrafish model shows altered motor behaviors. Front. Neural Circuits 2013, 7, 118. [Google Scholar] [CrossRef]
- Gabellini, C.; Pucci, C.; De Cesari, C.; Martini, D.; Di Lauro, C.; Digregorio, M.; Norton, W.; Zippo, A.; Sessa, A.; Broccoli, V.; et al. CRISPR/Cas9-Induced Inactivation of the Autism-Risk Gene setd5 Leads to Social Impairments in Zebrafish. Int. J. Mol. Sci. 2022, 24, 167. [Google Scholar] [CrossRef]
- Neri, P. Feature binding in zebrafish. Anim. Behav. 2012, 84, 485–493. [Google Scholar] [CrossRef]
- Zhang, Q.; Li, T.; Lin, J.; Zhang, Y.; Li, F.; Chen, X.; Wang, X.; Li, Q. Deficiency of nde1 in zebrafish induces brain inflammatory responses and autism-like behavior. iScience 2022, 25, 103876. [Google Scholar] [CrossRef]
- Saverino, C.; Gerlai, R. The social zebrafish: Behavioral responses to conspecific, heterospecific, and computer animated fish. Behav. Brain Res. 2008, 191, 77–87. [Google Scholar] [CrossRef]
- Rahmati-Holasoo, H.; Salek Maghsoudi, A.; Akbarzade, M.; Gholami, M.; Shadboorestan, A.; Vakhshiteh, F.; Armandeh, M.; Hassani, S. Oxytocin protective effects on zebrafish larvae models of autism-like spectrum disorder. Iran. J. Basic Med. Sci. 2023, 26, 316–325. [Google Scholar] [PubMed]
- Liu, X.S.; Wu, H.; Krzisch, M.; Wu, X.; Graef, J.; Muffat, J.; Hnisz, D.; Li, C.H.; Yuan, B.; Xu, C.; et al. Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene. Cell 2018, 172, 979–992.e6. [Google Scholar] [CrossRef] [PubMed]
- NINDS Amyotrophic Lateral Sclerosis (ALS). Available online: https://www.ninds.nih.gov/health-information/disorders/amyotrophic-lateral-sclerosis-als (accessed on 20 August 2023).
- Al-Chalabi, A.; Hardiman, O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013, 9, 617–628. [Google Scholar] [CrossRef] [PubMed]
- Masrori, P.; Van Damme, P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020, 27, 1918–1929. [Google Scholar] [CrossRef]
- van Es, M.A.; Hardiman, O.; Chio, A.; Al-Chalabi, A.; Pasterkamp, R.J.; Veldink, J.H.; van den Berg, L.H. Amyotrophic lateral sclerosis. Lancet 2017, 390, 2084–2098. [Google Scholar] [CrossRef]
- Brown, R.H.; Al-Chalabi, A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017, 377, 162–172. [Google Scholar] [CrossRef]
- Mejzini, R.; Flynn, L.L.; Pitout, I.L.; Fletcher, S.; Wilton, S.D.; Akkari, P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019, 13, 1310. [Google Scholar] [CrossRef]
- Chia, K.; Klingseisen, A.; Sieger, D.; Priller, J. Zebrafish as a model organism for neurodegenerative disease. Front. Mol. Neurosci. 2022, 15, 940484. [Google Scholar] [CrossRef] [PubMed]
- Martin, R.M.; Bereman, M.S.; Marsden, K.C. The Cyanotoxin 2,4-DAB Reduces Viability and Causes Behavioral and Molecular Dysfunctions Associated with Neurodegeneration in Larval Zebrafish. Neurotox. Res. 2022, 40, 347–364. [Google Scholar] [CrossRef] [PubMed]
- Yeh, T.H.; Liu, H.F.; Li, Y.W.; Lu, C.S.; Shih, H.Y.; Chiu, C.C.; Lin, S.J.; Huang, Y.C.; Cheng, Y.C. C9orf72 is essential for neurodevelopment and motility mediated by Cyclin G1. Exp. Neurol. 2018, 304, 114–124. [Google Scholar] [CrossRef] [PubMed]
- Ramesh, T.; Lyon, A.N.; Pineda, R.H.; Wang, C.; Janssen, P.M.; Canan, B.D.; Burghes, A.H.; Beattie, C.E. A genetic model of amyotrophic lateral sclerosis in zebrafish displays phenotypic hallmarks of motoneuron disease. Dis. Model Mech. 2010, 3, 652–662. [Google Scholar] [CrossRef]
- Laird, A.S.; Van Hoecke, A.; De Muynck, L.; Timmers, M.; Van den Bosch, L.; Van Damme, P.; Robberecht, W. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS ONE 2010, 5, e13368. [Google Scholar] [CrossRef] [PubMed]
- Armstrong, G.A.; Liao, M.; You, Z.; Lissouba, A.; Chen, B.E.; Drapeau, P. Homology Directed Knockin of Point Mutations in the Zebrafish tardbp and fus Genes in ALS Using the CRISPR/Cas9 System. PLoS ONE 2016, 11, e0150188. [Google Scholar] [CrossRef]
- Bose, P.; Tremblay, E.; Maios, C.; Narasimhan, V.; Armstrong, G.A.B.; Liao, M.; Parker, J.A.; Robitaille, R.; Wen, X.Y.; Barden, C.; et al. The Novel Small Molecule TRVA242 Stabilizes Neuromuscular Junction Defects in Multiple Animal Models of Amyotrophic Lateral Sclerosis. Neurotherapeutics 2019, 16, 1149–1166. [Google Scholar] [CrossRef] [PubMed]
- Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994, 330, 585–591. [Google Scholar] [CrossRef]
- Petrov, D.; Mansfield, C.; Moussy, A.; Hermine, O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front. Aging Neurosci. 2017, 9, 68. [Google Scholar] [CrossRef]
- Goldshtein, H.; Muhire, A.; Petel Legare, V.; Pushett, A.; Rotkopf, R.; Shefner, J.M.; Peterson, R.T.; Armstrong, G.A.B.; Russek-Blum, N. Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2020, 7, 1883–1897. [Google Scholar] [CrossRef]
- Patten, S.A.; Aggad, D.; Martinez, J.; Tremblay, E.; Petrillo, J.; Armstrong, G.A.; La Fontaine, A.; Maios, C.; Liao, M.; Ciura, S.; et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight 2017, 2, e97152. [Google Scholar] [CrossRef] [PubMed]
- Chaytow, H.; Carroll, E.; Gordon, D.; Huang, Y.T.; van der Hoorn, D.; Smith, H.L.; Becker, T.; Becker, C.G.; Faller, K.M.E.; Talbot, K.; et al. Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis. EBioMedicine 2022, 83, 104202. [Google Scholar] [CrossRef] [PubMed]
- Lattante, S.; de Calbiac, H.; Le Ber, I.; Brice, A.; Ciura, S.; Kabashi, E. Sqstm1 knock-down causes a locomotor phenotype ameliorated by rapamycin in a zebrafish model of ALS/FTLD. Hum. Mol. Genet. 2015, 24, 1682–1690. [Google Scholar] [CrossRef] [PubMed]
- Medvedev, S.P.; Shevchenko, A.I.; Zakian, S.M. Induced Pluripotent Stem Cells: Problems and Advantages when Applying them in Regenerative Medicine. Acta Naturae 2010, 2, 18–28. [Google Scholar] [CrossRef]
- Hallett, P.J.; Deleidi, M.; Astradsson, A.; Smith, G.A.; Cooper, O.; Osborn, T.M.; Sundberg, M.; Moore, M.A.; Perez-Torres, E.; Brownell, A.L.; et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell 2015, 16, 269–274. [Google Scholar] [CrossRef]
- Song, B.; Cha, Y.; Ko, S.; Jeon, J.; Lee, N.; Seo, H.; Park, K.J.; Lee, I.H.; Lopes, C.; Feitosa, M.; et al. Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson’s disease models. J. Clin. Investig. 2020, 130, 904–920. [Google Scholar] [CrossRef]
- Armijo, E.; Edwards, G.; Flores, A.; Vera, J.; Shahnawaz, M.; Moda, F.; Gonzalez, C.; Sanhueza, M.; Soto, C. Induced Pluripotent Stem Cell-Derived Neural Precursors Improve Memory, Synaptic and Pathological Abnormalities in a Mouse Model of Alzheimer’s Disease. Cells 2021, 10, 1802. [Google Scholar] [CrossRef]
- Strnadel, J.; Wang, H.; Carromeu, C.; Miyanohara, A.; Fujimura, K.; Blahovcova, E.; Nosal, V.; Skovierova, H.; Klemke, R.; Halasova, E. Transplantation of Human-Induced Pluripotent Stem Cell-Derived Neural Precursors into Early-Stage Zebrafish Embryos. J. Mol. Neurosci. 2018, 65, 351–358. [Google Scholar] [CrossRef]
Developmental Processes | Zebrafish | Rodents | Human | References |
---|---|---|---|---|
Establishment and maturation of BBB | 3 dpf—10 dpf | Pnd 1–3 | 23–32 g.w. | [99,100,101,102] |
Neurogenesis | 10 hpf—adult | E10.5–E19.5 | 6 g.w.–2.5 y.o. | [103,104,105,106] |
Peak in synaptic density/pruning | 8 dpf (in optic tectum) | Pnd 20–35 | 2–3 y.o. | [107,108,109,110] |
Astrocyte formation (observation of mature astrocytes) | 10 dpf in brain parenchyma. 2–4 dpf in spinal cord | E60–E95 | 12–40 g.w. | [101,102,111,112,113] |
Oligodendrocyte maturation | 60 hpf | Pnd 0—adult (peak at pnd 14) | 15–28 g.w. | [114,115,116] |
Myelin development | 60 hpf—adult | Pnd 7–90 | 28—adult | [116,117] |
Mode of Drug Administration | Protocol | Advantages | Challenges |
---|---|---|---|
Direct administration techniques | |||
Bath immersion | Drug/therapeutic compound is directly dissolved into nutritive water media of the zebrafish. |
|
|
Microinjections |
|
|
|
Indirect administration techniques | |||
Oral administration |
|
|
|
Genetic manipulation |
|
|
|
Novel drug delivery systems | |||
Nanoparticles |
|
|
|
Hydrogels |
|
|
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chaoul, V.; Dib, E.-Y.; Bedran, J.; Khoury, C.; Shmoury, O.; Harb, F.; Soueid, J. Assessing Drug Administration Techniques in Zebrafish Models of Neurological Disease. Int. J. Mol. Sci. 2023, 24, 14898. https://doi.org/10.3390/ijms241914898
Chaoul V, Dib E-Y, Bedran J, Khoury C, Shmoury O, Harb F, Soueid J. Assessing Drug Administration Techniques in Zebrafish Models of Neurological Disease. International Journal of Molecular Sciences. 2023; 24(19):14898. https://doi.org/10.3390/ijms241914898
Chicago/Turabian StyleChaoul, Victoria, Emanuel-Youssef Dib, Joe Bedran, Chakib Khoury, Omar Shmoury, Frédéric Harb, and Jihane Soueid. 2023. "Assessing Drug Administration Techniques in Zebrafish Models of Neurological Disease" International Journal of Molecular Sciences 24, no. 19: 14898. https://doi.org/10.3390/ijms241914898